Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nine Catalysts For China Biopharma In 2019

Executive Summary

After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.

You may also be interested in...



China Releases List To Encourage Competition

China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.

Bring Them On: China Releases Generics List To Encourage Competition

China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.

China - The Next Promised Land For Korean Biosimilars?

Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market for their biosimilars amid the Chinese government's increasing policy support for biologics and generics, and rising competition elsewhere. Part of their tailored entry approach includes striking deals with local partners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel